Protect-1, a prospective randomized oral therapy evaluation of CCX282-B (Traficet-EN) in Crohn's disease trial
Main Authors: | Bekker, P, Petryka, R, Vanasek, T, Niv, Y, Marlicz, K, Haagen-Nielsen, O, Dahelrup, J, Dotan, I, Compel, V, Keshav, S, Schall, T |
---|---|
Format: | Conference item |
Published: |
2008
|
Similar Items
-
PROTECT-1: A prospective randomized trial of CCX282-B (Traficet-EN), a novel oral therapy targeting chemokine receptor 9 in Crohn's disease
by: Keshav, S, et al.
Published: (2007) -
Traficet-EN (CCX282-B), an orally active inhibitor of chemokine receptor CCR9, for treatment of Crohn's disease
by: Bekker, P, et al.
Published: (2007) -
PROTECT-1 Maintenance Phase Study Results demonstrate efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Crohn's Disease
by: Bekker, P, et al.
Published: (2009) -
PROTECT-1 Study Demonstrated Efficacy of the Intestine-Specific Chemokine Receptor Antagonist CCX282-B (Traficet-EN) in Treatment of Patients with Moderate to Severe Crohn's Disease
by: Keshav, S, et al.
Published: (2009) -
Ccx282-B, an orally active inhibitor of chemokine receptor Ccr9, shows anti-inflammatory and clinical activity in the treatment of Crohn's disease
by: Keshav, S, et al.
Published: (2007)